Fungi from the Candida genus are widespread commensals and, at the same time, are the leading cause of fungal infections worldwide. For instance, vulvovaginal candidiasis (VVC) affects approximately 75% of women at least once in their lifetime, remaining the second most common gynecological infection. On the contrary, hospital-acquired fungal bloodstream infections (BSIs), although less frequent, are characterized by a high mortality rate. Undoubtedly, the main reason for this situation are virulence factors that these yeast-like fungi can produce, and the ability to form a biofilm is one of the most important of them. Due to the low effectiveness of classic antimycotics against Candida biofilms, an intense search for new drugs capable of eradicating this structure is highly demanded. One of the most promising groups of compounds exhibiting such properties are antimicrobial peptides (AMPs). This study focuses on a comparison of the efficacy of Omiganan and fluconazole alone and in combination against Candida strains isolated from BSIs. The obtained results are consistent with our previous reports on the effectiveness of Omiganan against clinical strains isolated from VVC. This is also the first report on the combinatory application of Omiganan in the context of fungal BSI. The majority of combinations with fluconazole showed an additive effect, as well as a synergistic effect in the range of certain concentrations. Importantly, such effects are visible at concentrations much lower than for those compounds used individually. Potentially, this entails the possibility of limiting the adverse effects (e.g., toxicity) of Omiganan and fluconazole applied in vivo, thus improving the safety profile of this particular antifungal therapy.

Particulate matter (PM) and NO2 induce pathophysiological changes which contribute to an increased incidence of acute cardiovascular (CV) and respiratory (Rp) events. To analyze the relationship between air quality and the frequency of admissions to the emergency department (ED) due to the CV diseases and Rp causes. The study analyzed the reasons for admissions to the ED during the cold periods from January 2017 to January 2020. These data were combined with the average daily concentrations of NO2, PM2.5 and PM10, and the individual air quality indexes (IAQIs) for these pollutants. Our analyses have shown that 3468 (11.4%) and 1053 (3.46%) of all 30,419 analyzed patients were admitted to the ED for CV and Rp reasons, respectively. Cardiovascular patients were significantly more often admitted to the ED when the IAQI for NO2 was worse than very good, and the IAQI for PM2.5 or PM10 was worse than good. In such periods, diagnoses such as ischemic heart disease (IHD) or syncope were statistically more common and the risk of admission of a patient with a diagnosis such as IHD, heart failure (HF), syncope, stroke, or transient ischemic attack (TIA) was increased. Registered deaths occurred significantly more often among patients admitted on days with moderate or worse than moderate air quality determined in relation to PM10 in comparison to days with very good or good air quality (0.35% and 0.23%, respectively, p = 0.04). Air quality significantly affects the admissions to the ED for CV and Rp reasons and has an impact on mortality.

Background: Research confirms that Candida spp. incubated with methotrexate develop multi-drug resistance to azoles, but it is not clear whether this phenomenon occurs in vivo in patients treated with cytostatics. The aim of the study was to assess whether systemic methotrexate therapy induces resistance to azoles among endogenous Candida strains in patients with rheumatological diseases. Methods: The test group consisted of 52 rheumatological patients on methotrexate therapy, who have never been exposed to fluconazole. The control group was composed of 49 individuals who have never been exposed to either methotrexate or fluconazole. Oral swab and clinical information were obtained from each participant. The acquired material was cultured, then each strain was isolated and identified (MALDI TOF). Subsequently, minimal inhibitory concentration (MIC) for fluconazole was determined. Results: MIC values ranged from <0.125 to 64 µg/mL with the most common result <0.125 µg/mL. Samples obtained from 4 patients of the test group and 2 patients of the control group contained strains resistant to fluconazole. Conclusions: Despite slightly higher incidence of fluconazole-resistant strains among patients on systemic methotrexate therapy, we found no solid evidence to support the hypothesis that methotrexate induces resistance to azoles among endogenous Candida strains in patients with rheumatological diseases.

Powierzchnie sprzętów do ćwiczeń mają częsty kontakt ze skórą i wydzielinami osób ćwiczących, w związku z czym stanowią potencjalny wektor przenoszenia drobnoustrojów. W celu ograniczenia transmisji zalecana jest dezynfekcja sprzętu, wykonywana przez użytkownika po każdym zakończonym ćwiczeniu. Podczas prowadzenia badań pobrano 100 wymazów z losowo wybranych powierzchni sprzętów do ćwiczeń w czterech wrocławskich siłowniach i klubach fitness. Niektóre powierzchnie badano przed i po dezynfekcji preparatem dostępnym na terenie siłowni.

BACKGROUND Rhabdomyolysis, although typically associated with immobilization, trauma, or the use of certain medications, can also manifest as a severe and potentially life-threatening complication of dermatomyositis. This condition results from the breakdown of skeletal muscle, presenting with symptoms such as myalgia, muscle weakness, and myoglobinuria. Although high-dose steroids are the treatment of choice in cases of dermatomyositis-related rhabdomyolysis, they can trigger the onset of steroid-induced myopathy. CASE REPORT A 50-year-old woman with bilateral muscle weakness, myalgia, erythematous-papular rash, urine abnormalities, and significantly elevated liver transaminases was mistakenly admitted to the Gastroenterology Department due to suspected acute liver damage. After initial management, the patient was diagnosed with dermatomyositis-related rhabdomyolysis. The introduction of high-dose systemic steroid therapy resulted in a deterioration of her clinical condition and triggered the appearance of additional symptoms (dysphagia, dysphonia, difficulty breathing and coughing effectively). Due to the suspicion of the acute steroid-induced myopathy, the steroid was promptly discontinued, which resulted in a noticeable reduction in the severity of the new symptoms. After 2 days, we restarted steroid treatment at a lower dose, along with intravenous immunoglobulin therapy, obtaining gradual clinical improvement. CONCLUSIONS Deterioration of general condition or new symptoms appearing after steroid administration should always raise suspicion of acute steroid-induced myopathy, which may overlap with dermatomyositis. Differentiating between the exacerbation of myositis symptoms and steroid-induced myopathy is problematic and not always possible. In case of suspected steroid-induced myopathy, steroid should be used at the lowest effective dose or replaced by a non-steroidal agent.

Previous studies have demonstrated that Candida spp. isolates exposed in vitro to the folic acid antagonist methotrexate may develop multidrug cross-resistance to azole antifungals. The aim of this study was to determine whether systemic therapy with antineoplastic antifolates—pemetrexed or methotrexate—constitutes a risk factor for colonization or infection with fluconazole-resistant yeasts. The study group comprised 44 cancer patients who received high-dose systemic antifolate therapy, while the control group consisted of 48 patients without prior exposure to either methotrexate or pemetrexed. Oral swabs and relevant clinical data were collected from all participants. In total, 109 fungal strains representing 13 species were isolated, identified, and subsequently tested for fluconazole susceptibility. Fluconazole-resistant isolates were identified in 4 out of 44 (9.1%) antifolate-treated patients and in 3 out of 48 (6.3%) control patients. Our findings suggest that, although this phenomenon occurs in vitro, systemic antineoplastic antifolate therapy does not induce azole resistance among endogenous yeast species in vivo.